Blackstone Inc’s Aprea Therapeutics APRE Stock Holding History

Blackstone Inc’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-830	Closed	-$5.49K	–	167
2022 Q4	$5.49K	Hold	830	–	–	﹤0.01%	173
2022 Q3	$11K	Hold	830	–	–	﹤0.01%	217
2022 Q2	$12K	Hold	830	–	–	﹤0.01%	245
2022 Q1	$31K	Hold	830	–	–	﹤0.01%	242
2021 Q4	$48K	Hold	830	–	–	﹤0.01%	500
2021 Q3	$85K	Buy	+830	New	+$75.4K	﹤0.01%	552

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Blackstone Inc's APRE Position: Q1 2023 in Review

Blackstone Inc sold out of Aprea Therapeutics (APRE) in Q1 2023, closing a stake of 830 shares — an estimated $5.49K sold.

Blackstone Inc first reported a position in APRE in Q3 2021 and held it in 6 quarters. The position peaked at $85K in Q3 2021. 18 funds tracked by Wall St. Rank hold APRE as of Q1 2023.

Blackstone Inc reported no remaining Aprea Therapeutics position as of Q1 2023 after selling out during the quarter.
Blackstone Inc sold 830 Aprea Therapeutics shares in Q1 2023, an estimated $5.49K.
Blackstone Inc first reported a position in Aprea Therapeutics in Q3 2021 and held it in 6 quarters.
Blackstone Inc's Aprea Therapeutics position peaked at $85K in Q3 2021.
18 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2023.

Based on Blackstone Inc's 13F filing for Q1 2023, filed 15 May 2023.